T Cell Regulation of Cutaneous Malignancy

T 细胞对皮肤恶性肿瘤的调节

• 批准号: 6677357
• 负责人: MICHAEL GIRARDI
• 金额: $ 36.38万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6677357
• 关键词: T lymphocyte; cellular immunity; chemical carcinogenesis; cutaneous papilloma; cytolysins; gene expression; gene induction /repression; immunoregulation; interferon gamma; interleukin 10; keratinocyte; laboratory mouse; neoplasm /cancer immunology; neoplastic process; osteopontin; plasmids; pore forming protein; skin neoplasms; squamous cell carcinoma; syndecan; transfection

DESCRIPTION (provided by applicant): There is intensifying interest in tumor immunosurveillance and the prospect of cancer immunotherapy. This is principally founded on the concept that a developing tumor can be recognized by systemic T cells that will kill it either directly or via TH1-mediated cytokine effects. However, this view largely ignores the potential involvement of local T cells that are resident at many sites of carcinoma development, and it fails to accommodate the increasing appreciation of the complexity of the cell-mediated immune response that can involve a variety of regulatory as well as effector T cells. Therefore, we have set out to understand the individual and distinct contributions of defined components of the immune system to the regulation of cutaneous malignancy. The work builds on recently published experiments using murine models of carcinogenesis that collectively have exposed the complexity of the immune response and indicate a variety of issues that need to be considered in our understanding of immunosurveillance and the design of immunotherapy strategies. The hypothesis proposed is that various subsets of alpha-beta and gamma-delta T cells act differentially to regulate cutaneous malignancy. The major goals of the proposed studies are to identify those specific T cell subsets, begin to elucidate their mechanism(s) of action, and demonstrate critical effects of the immune system on tumor development previously revealed by altered gene expression profiles of tumors developing in hosts of different immunocompetence. To achieve these goals, the following four (4) specific aims are proposed: Aim 1 -Determine whether Vgamma5+ DETC alone are sufficient to mediate protection against cutaneous malignancy, and the degree to which systemic recirculating gamma-delta+ T cells add or subtract from tumor protection. Aim 2 -Determine the relative anti- and pro-tumor properties of specific subsets of alpha-beta T cells as determined by their effects on tumor development (i.e. papilloma formation) and progression to carcinoma. Aim 3 - Assess the role of several key immune effector molecules (IFNgamma, IL-10, FasL, and perforin) in gamma-delta and alpha-beta T cell regulation of cutaneous T cell deficient mice following selective repopulation of T cell deficient mice with various subsets of T cells from mice genetically deficient in immune effector molecules. Aim 4 - Analyze in vivo the biological effects of plasmid driven over-expression vs. inhibition of expression (using RNAi) of collapsin, osteopontin and syndecan-1 by PDV tumor cells in the presence and absence of immune components.

描述（由申请人提供）：人们对肿瘤免疫监测和癌症免疫治疗的前景越来越感兴趣。这主要是基于一个概念，即发展中的肿瘤可以被全身T细胞识别，直接或通过th1介导的细胞因子作用杀死它。然而，这种观点在很大程度上忽略了驻留在癌症发展许多部位的局部T细胞的潜在参与，并且它无法适应细胞介导的免疫反应的复杂性，这种免疫反应可能涉及各种调节性T细胞和效应T细胞。因此，我们开始了解免疫系统中特定成分对皮肤恶性肿瘤调节的个体和独特贡献。这项工作建立在最近发表的使用小鼠致癌模型的实验基础上，这些实验共同暴露了免疫反应的复杂性，并指出了我们对免疫监视和免疫治疗策略设计的理解中需要考虑的各种问题。